Atossa Therapeutics, Inc.

Clinical-stage biopharmaceutical company developing (Z)-endoxifen, a selective estrogen receptor modulator/degrader, in oncology and rare diseases including Duchenne Muscular Dystrophy and McCune-Albright Syndrome.